MARKET

SYRS

SYRS

Syros Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

11.91
-0.16
-1.33%
After Hours 16:00 08/14 EDT
OPEN
12.03
PREV CLOSE
12.07
HIGH
12.05
LOW
11.78
VOLUME
147.36K
TURNOVER
--
52 WEEK HIGH
12.75
52 WEEK LOW
4.260
MARKET CAP
545.03M
P/E (TTM)
-7.0282
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average SYRS stock price target is 14.86 with a high estimate of 20.00 and a low estimate of 10.00.

EPS

SYRS News

More
Syros Pharmaceuticals, Inc. (SYRS) Reports Q2 Loss, Tops Revenue Estimates
Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of 5.00% and 45.57%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 08/06 13:55
Syros Reports Second Quarter 2020 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter ended June 30, 2020 and provided an update on recent accomplishments and upcoming events.
Business Wire · 08/06 11:31
Will Syros Pharmaceuticals, Inc. (SYRS) Report Negative Q2 Earnings? What You Should Know
Syros Pharmaceuticals, Inc. (SYRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 07/30 16:34
Syros to Report Second Quarter 2020 Financial Results on Thursday, August 6, 2020
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, August 6, 2020 to report its second quarter 20
Business Wire · 07/30 12:30
BGFV, CYH, GAIN and SYRS among after-hours movers
Seeking Alpha · 07/28 21:46
The Daily Biotech Pulse: Opko Wins CDC Contract, Novartis Lowers Guidance, Pieris Study Placed On Partial Clinical Hold
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 20)
Benzinga · 07/21 11:59
The Daily Biotech Pulse: FDA Nod For Osmotica, OptiNose Strikes Co-promotion Deal, Orphan Drug Designation For AnaptysBio
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 8)
Benzinga · 07/09 12:09
Flagship Pioneering's Scientists Invent a New Category of Genome Engineering Technology: Gene Writing
PR Newswire · 07/07 13:00

Industry

Pharmaceuticals
-0.37%
Pharmaceuticals & Medical Research
-0.38%

Hot Stocks

Symbol
Price
%Change

About SYRS

Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines. The Company's drug programs include SY-1425 (retinoic acid receptor alpha (RARa) agonist) and SY-1365 (cyclin-dependent kinase 7 (CDK7) inhibitor). SY-1425 (tamibarotene) is an oral, potent and selective agonist, or activator, of the transcription factor RARa. SY-1365 is a small molecule inhibitor of the transcriptional kinase known as CDK7. The Company is using its platform to analyze gene expression programs across additional cancers, solid tumors, inflammatory diseases and other diseases to find optimal points of therapeutic intervention in patients.
More

Webull offers kinds of Syros Pharmaceuticals Inc stock information, including NASDAQ:SYRS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SYRS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SYRS stock methods without spending real money on the virtual paper trading platform.